Chief Executive Officer
Raman Singh is Chief Executive Officer (CEO) of Juniper Biologics overseeing its global pharmaceutical operations.
Prior to Juniper, Raman was CEO for Mundipharma and its operations in Latin America, the Middle East Africa and the Asia Pacific as well as the company’s Global Consumer Healthcare business.
Before joining Mundipharma in October 2011, Raman served as vice-president of commercial operations for emerging markets at GSK. In his role, he oversaw all aspects of the brand’s commercial operations across its emerging markets. Raman has previously held positions at AbbVie as the regional director in Australia and New Zealand, and general manager for Korea, as well as various sales, marketing and strategy positions at Bayer.
Raman also sits on the board for Liquidia, a late-stage clinical bio pharmaceutical company focused on the development and commercialisation of novel products. He is the only non-USA based Board Member. During his term, he successfully oversaw the IPO in NASDAQ, USA on July 25th, 2016 as well as the acquisition of RareGen LLC, a portfolio company of PBM Capital Group.
A champion of digital healthcare, Raman also sits on the boards of Biofourmis Healthcare and Neuroglee Therapeutics.
Chief Financial Officer
Jason Hwang serves as the Chief Financial Officer of Juniper Biologics, where he is responsible for overseeing the global financial operations and strategy of the organization.
Jason boasts an impressive background with over 25 years of valuable experience in investment banking and capital markets. He has a strong track record of successfully launching IPOs and orchestrating turnarounds for underperforming businesses, showcasing his ability to drive success.
Prior to joining Juniper Biologics, Jason held various positions in global financial institutions in both Hong Kong and Korea. In his most recent role, he held the role of Senior Managing Director and Head of the Capital Markets Division at Shinhan Investment Corp. In this role, Jason led a team of 60+ members across five departments, specializing in Korean equity capital markets, particularly focusing on IPOs, M&A, and SME sectors, and actively engaged in pre-IPO investments. At Shinhan Investment Corp, he was responsible for the groundbreaking $11 billion LG Energy Solution IPO, which marked the largest IPO in Korea to date. Notably, Jason also served as the Executive Director and Head of Korea Capital Markets at JPMorgan Securities.
Jason has a Bachelor’s Degree in Industrial Engineering from Columbia University.
Chief Commercial Officer
Benedict Ong is Chief Commercial Officer of Juniper Biologics overseeing its global marketing and commercial operations.
Prior to joining Juniper, Benedict has many years of commercial experiences in Pharmaceuticals, Next Generation Sequencing Diagnostics and Medical Devices focusing in the therapeutic area of oncology and haematology. He was holding to various local and regional sales and marketing positions in various established MNCs including Janssen and Roche.
Benedict graduated with a Bachelor in Pharmacy from National University of Singapore and is currently a registered pharmacist. He also holds a Master of Business Administration from the University of Birmingham.
Vice President Communications and Corporate Affairs
Stephenie is an accomplished and experienced global corporate communications and marketing professional with a proven track record in b2b and b2c marketing and communications across multiple industries including broadcasting, financial services and insurance. She has more than 20 years of proven expertise in Brand and PR strategy, issues and crisis management, reputation management, internal and change communications as well as marketing and sponsorship activation.
Prior to Juniper Biologics, Stephenie was Chief Communications Officer at Mundipharma. She has also held key strategic communications roles within the financial services sector. These included serving as the Head of Communications at Barclays as well as the Director of Communications for Aviva Asia.
She also previously led the regional marketing communications function for ESPN Star Sports as Vice President, spearheading rebranding and corporate positioning strategies for the organization, as well as at Media Monitors where she advised clients from the Singapore government as well as Fortune 500 companies on the effectiveness of their communications strategies.
Stephenie holds a Master of Science in Organizational Communications and a Bachelor of Science in Mass Communications and Journalism from Southern Illinois University.
Head of Legal and Compliance
Rachel is an experienced lawyer, qualified in England & Australia with over 25 years’ experience across different industries. In the last 15 years, she has been working in the healthcare industry with companies like Boston Scientific, Mundipharma and Lonza, providing robust legal and anti-corruption compliance advice and support in APAC, Latin America and Middle East. She has a broad international experience having lived and worked in 5 countries and has a wide-ranging cultural knowledge.
She is experienced in handling a broad spectrum of legal and compliance issues in business as well as different markets including M&As, market entry, litigation (US and ex-US), IP and commercial transactions.
Vice President and Regional General Manager of ANZ
Maulik Shroff serves as Vice President and General Manager for Juniper Biologics in Australia and New Zealand. He has more than 20 years experience in the pharmaceutical industry and has worked across geographies such as India, Australia and the Asia Pacific region.
Maulik graduated with a Bachelors of Science in Bio Chemistry from India and also holds a Masters of Engineering in Information Technology from RMIT University in Melbourne Australia.
He started his pharmaceutical journey in India working for Emcure in sales and sales management roles. He continued his career in Australia working for Eli Lilly, Novartis and Mundipharma prior to joining Juniper Biologics. Over these years Maulik has successfully worked in various commercial and leadership roles. His leadership has spanned over different therapeutic areas including oncology.
Maulik is passionate about building high performing teams to drive commercial innovation and improve patient outcomes.
Vice President and Regional General Manager of SEA
Suresh Pragasam serve as Vice President and Regional General Manager of Juniper Biologics overseeing its South East Asia pharmaceutical operations.
Prior to Juniper, Suresh was Regional General Manager for Mundipharma and its operations in South East Asia, HongKong and Taiwan.
Before joining Mundipharma in March 2016, Suresh served as Strategic Development Director and Commercial Director for Sanofi Pharmaceuticals. In his role, he oversaw all aspects of the company’s strategic formulations and operations, Business Development and Commercial Operations for the company’s pharmaceutical business across Malaysia and Singapore. Suresh has previously held positions at UCB Pharma and GlaxoSmithKline Pharmaceuticals as the Commercial Director for Malaysia and Singapore, as well as various sales, marketing and commercial Excellence positions at GlaxoSmithKline Pharmaceuticals.
Suresh graduated with a Masters in Business Administration from Edith Cowan University, Australia.
Vice President and Regional General Manager of MEA
Haytham Ramzy serves as Vice President & General Manager, Middle-East & Africa for Juniper Biologics.
Haytham has over 16 years of pharmaceutical experience where he is most recently the Cluster Head in Egypt and Near East. Haytham is a strategic and results-oriented leader with a successful track record in the pharmaceutical industry, partnering CEOs and Boards, leading stakeholder and employee engagement.
As Vice President & General Manager, MEA, Haytham will provide strategic direction to the region’s operations including all sales, marketing, reporting and compliance plans. He will be responsible for establishing Juniper Biologics operations and building long-term partnerships with healthcare professionals, patient groups and government bodies. He will be an important link between Juniper Biologics and channel partners in the MEA region, and will be accountable for all business development activities, with the aim of growing Juniper Biologics’ business portfolio.